(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 76.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.21%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $29,102,000.On average, 7 Wall Street analysts forecast TNXP's revenue for 2026 to be $980,318,230, with the lowest TNXP revenue forecast at $857,208,180, and the highest TNXP revenue forecast at $1,170,557,388. On average, 6 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,936,350,610, with the lowest TNXP revenue forecast at $1,395,990,447, and the highest TNXP revenue forecast at $2,683,277,705.
In 2028, TNXP is forecast to generate $2,703,687,423 in revenue, with the lowest revenue forecast at $1,764,840,370 and the highest revenue forecast at $4,177,989,446.